CriticalCombined oral contraceptives – antimineralocorticoid progestin×Antifibrinolytics, amino acids
Updated · Methodology
Mechanism
Tranexamic acid slows the breakdown of blood clots, and combined hormonal contraceptives on their own raise the risk of venous thromboembolism and of arterial thrombosis such as stroke and myocardial infarction (tranexamic acid label, US Food and Drug Administration, FDA). When the two are combined, the risk of venous thromboembolism and stroke may rise further, especially in women who are obese or smoke, above all smokers over 35 (tranexamic acid FDA label). Women using combined hormonal contraception were excluded from the tranexamic acid tablet trials, but there have been US postmarketing reports of venous and arterial thrombosis with this combination (tranexamic acid FDA label). In the Spanish tranexamic acid SmPCs, the same higher thrombosis risk explains the caution with oral contraceptives. Contraceptives with drospirenone may carry up to twice the venous thromboembolism risk of products with levonorgestrel (tranexamic acid and drospirenone/ethinylestradiol summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS).
Symptoms
Deep vein thrombosis causes swelling of one leg or foot, leg pain on standing or walking, and warmth and redness of the leg skin. Pulmonary embolism causes sudden shortness of breath or fast breathing, cough sometimes with blood, sharp chest pain, severe light-headedness and a fast or irregular heartbeat (drospirenone/ethinylestradiol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Stroke starts with sudden numbness or weakness of the face, arm or leg, usually on one side, trouble speaking, walking or seeing, a severe headache, and sometimes loss of consciousness (drospirenone/ethinylestradiol SmPC, AEMPS). Retinal vein and artery occlusion has been reported with tranexamic acid and causes visual disturbances (tranexamic acid label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated in the US Food and Drug Administration (FDA) label for tranexamic acid tablets: the tablets are not given to women who use combined hormonal contraceptives, and drospirenone/ethinylestradiol is such a contraceptive (tranexamic acid FDA label; drospirenone/ethinylestradiol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For intravenous tranexamic acid, under the US label, avoid combining it with medicines that raise the thrombosis risk, including hormonal contraceptives, and use an effective non-hormonal contraceptive method during treatment (tranexamic acid injection FDA label). The Spanish SmPCs are softer: in women taking oral contraceptives, tranexamic acid is given with caution, and thromboembolic risk factors are assessed before treatment (tranexamic acid SmPCs, AEMPS). Tranexamic acid is contraindicated in patients with a history of venous or arterial thrombosis (tranexamic acid SmPCs, AEMPS, and FDA label). Drospirenone/ethinylestradiol is contraindicated in women with current or past venous or arterial thrombosis or a high thrombotic risk (drospirenone/ethinylestradiol SmPC, AEMPS). For heavy menstrual bleeding, tranexamic acid tablets are started only after bleeding has begun, at 2 tablets of 500 mg 3 times a day for no more than 4 days and no more than 4 g a day (tranexamic acid SmPC, AEMPS). Explain the warning signs of thrombosis and stroke to the woman: with leg swelling or pain, sudden breathlessness, chest pain, numbness on one side of the body or trouble speaking, she should seek emergency care at once and say she takes a contraceptive (drospirenone/ethinylestradiol SmPC, AEMPS). If visual disturbances appear, stop tranexamic acid at once and refer the woman to an ophthalmologist (tranexamic acid SmPCs, AEMPS, and FDA label). If thrombosis is suspected, stop the contraceptive (drospirenone/ethinylestradiol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Tranexamic acid tablets, Nordic Pharma (NDA 022430, tranexamic acid) prescribing information (2025)– FDA, DailyMed setid 031bf7c2-3b07-469d-bc5a-31fc6238e25f (Nordic Pharma, NDA 022430), revisión 09/2025 (versión 7), secciones 4, 5.1 y 7.1
- FDA: Cyklokapron (tranexamic acid) injection prescribing information (2025)– FDA, DailyMed setid 6e89a7d9-4da4-42aa-b7f8-c602c24eefe5 (Pfizer), revisión 09/2025 (versión 34), secciones 5.2, 7 y 8.3
- AEMPS: Ficha técnica: Ácido tranexámico, Amchafibrin 500 mg comprimidos recubiertos con película (nº registro 88279), sección 4.4 (2026)– AEMPS, CIMA, nº registro 88279 (Amchafibrin 500 mg comprimidos recubiertos con película, Viatris), revisión 06/2026, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Ácido tranexámico Zentiva 500 mg comprimidos (nº registro 80781), sección 4.4 (2026)– AEMPS, CIMA, nº registro 80781 (Ácido tranexámico Zentiva 500 mg comprimidos recubiertos con película EFG), revisión 07/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Drospirenona/etinilestradiol, Yasmin 3 mg/0,03 mg comprimidos (nº registro 63576), sección 4.4 (2024)– AEMPS, CIMA, nº registro 63576 (Yasmin 3 mg/0,03 mg comprimidos recubiertos con película, Bayer), revisión 05/2024, secciones 4.3 y 4.4